DAMOCLES
Primary tabs
About your organization / profile
DAMOCLES is a French deep-tech start-up, a spin-off of two INSERM laboratories, specializing in in vitro diagnostics.
It develops rapid (less than 3 hours) and automated antibiotic sensitivity tests (AST). The patented technology allows medical laboratories to deliver the results the day after the sample is taken and thus reduce the Time to Care by half. The DAMOCLES ONE+ machine also brings flexibility to current automated production lines, greatly increasing productivity to adapt to the challenges of the fight against antibiotic resistance.
DAMOCLES is currently composed of a team of 10 people. In 2022, we validated a clinical study on 100 bacterial isolates and 50 positive blood cultures with agreements > 98% compared to the gold standard. Several private laboratories and hospitals have shown interest in the technology.
DAMOCLES ONE+ will be marketed at the end of 2024 for research laboratories and animal health. The IVD CE mark is planned for the end of 2026, allowing the launch of the commercialisation in human health.
We are currently seeking €2M for the commercialisation of the technology for research laboratories and the clinical qualification of the machine in human health.
Network (0)
There are no organizations in the network.
